Search Results
Feb 11, 2026, 16:15 ET Albemarle Reports Fourth Quarter and Full Year 2025 Results
and $1.9 million of charges for asset retirement obligations at a site not part of our operations, partially offset by $19.8 million of income from PIK dividends of the preferred equity in a Grace subsidiary prior to redemption and a $2.4 million gain primarily resulting from the adjustment of indemnification
More news about: Albemarle Corporation
Feb 05, 2026, 09:35 ET $207B Market Shift: The Race for Fast Track Approval in Oncology
fulvestrant for PIK3CA-mutant HR+/HER2- locally advanced or metastatic breast cancer following progression on CDK4/6 inhibitor treatment. The designation was supported by clinical data from the ReDiscover trial with 600mg BID fasted and 400mg BID fed doses showing comparable exposures across all PIK3CA mutations."This
More news about: USA News Group
Feb 03, 2026, 17:32 ET Publicly listed BDCs lag unlisted BDC peers as credit quality gap widens, Heron Finance analysis finds
BDCsUsing Q3 2025 data from an analysis of 71 BDCs, Heron evaluated multiple portfolio health indicators of BDCs:Payment-in-kind (PIK) interestHigher PIK levels may indicate borrowers deferring cash interest payments due to financial strain.Publicly listed BDCs:
More news about: Heron Finance
Jan 28, 2026, 06:17 ET Heron Finance releases "State of Private Credit Benchmark Report" analyzing 71 of the largest private credit funds
across credit quality measures such as PIK interest and non-accruals."Key findings from the State of Private Credit Benchmark Report (Q1 2026 edition) include:PIK interest remained within historical norms. Payment-in-kind (PIK) interest declined modestly in Q3 2025
More news about: Heron Finance
Jan 21, 2026, 10:08 ET Jeffrey Modell Foundation Awards $550,000 to Innovative Primary Immunodeficiency Research
Centre for Cancer Biology, Adelaide University (Adelaide, Australia) for a project titled "PIK3CG deficiency: A novel hyper-IgE syndrome" ($50,000)The Translational Research Program was launched by JMF in 2013 to invest in research
More news about: Jeffrey Modell Foundation
Jan 14, 2026, 01:32 ET Huawei Smart PV ve ESS 2026'nın En İyi 10 Trendini Açıkladı
Yenilenebilir enerji üretimindeki dalgalanmaları yumuşatır, enerji kaynağı istikrarını artırır, enerji piyasalarına katılır ve frekans düzenleme ve pik tıraşlama gibi yan hizmetler sağlarlar.Trend 3: Üretim-şebeke-yük-depolama Sinerjisi Bölgesel Özerkliği ve Güç Arzının Küresel Koordinasyonunu
More news about: Huawei Digital Power
Dec 23, 2025, 09:09 ET Automotores Gildemeister SpA Announces Expiration and Final Results of Previously Announced Exchange Offers by AG Chile Holding II SpA for Outstanding 7.50% Junior Secured Notes due 2027 and 10.00% Subordinated Notes due 2035 and Related Consent Solicitations
to exchange (the "Existing Junior Notes Exchange Offer") any and all of their outstanding Existing Junior Notes for new 7.50% Senior Secured PIK Toggle Notes due 2032 (the "New 2032 Notes") to be issued by AG Chile Holding II SpA, a newly incorporated holding company (the "Issuer"),
More news about: Automotores Gildemeister SpA
Dec 23, 2025, 07:11 ET Heron Finance review: How Heron's private credit investing strategy performed against peer funds
Heron Finance (net of Heron's fees): 9.5%Peer Group (net of fund fees, gross of Heron's fees): 9.0%Payment-in-Kind (PIK) Interest:Heron Finance: 3.1%Peer Group: 4.9%Loan Default:Heron Finance:
More news about: Heron Finance
Dec 17, 2025, 16:10 ET Gloo Holdings, Inc. Reports Third Fiscal Quarter 2025 Financial Results
Debt assumed through PIK interest
More news about: Gloo
Dec 15, 2025, 08:30 ET Automotores Gildemeister SpA Announces Early Results of Previously Announced Exchange Offers by AG Chile Holding II SpA for Outstanding 7.50% Junior Secured Notes due 2027 and 10.00% Subordinated Notes due 2035 and Related Consent Solicitations
to exchange (the "Existing Junior Notes Exchange Offer") any and all of their outstanding Existing Junior Notes for new 7.50% Senior Secured PIK Toggle Notes due 2032 (the "New 2032 Notes") to be issued by AG Chile Holding II SpA, a newly incorporated holding company (the "Issuer"),
More news about: Automotores Gildemeister SpA
Dec 10, 2025, 14:16 ET Menarini Group apresenta os dados da fase 2 da combinação de elacestranto (ORSERDU®) em pacientes com câncer de mama metastático (mBC) ER+, HER2- no San Antonio Breast Cancer Symposium 2025 (SABCS)
*PIK3CAmut8,3 [3,6 - 10,2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 14:02 ET Menarini Group presenta datos de combinación de fase 2 de Elacestrant (ORSERDU®) en pacientes con cáncer de mama metastásico (CMM) ER+, con HER2 en el Simposio de Cáncer de Mama 2025 en San Antonio
*PIK3CAmut8,3 [3,6 - 10,2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 11:00 ET Strategic Value Partners Co-leads €600m Investment in Celsa
steel producers in Europe, has announced the successful completion of its refinancing. As part of the transaction, Celsa is issuing €600m of HoldCo PIK notes, co-led by funds managed by Strategic Value Partners, LLC and its affiliates (together, "SVP"), alongside a €1.2bn issuance of senior secured bonds.
More news about: Strategic Value Partners
Dec 10, 2025, 10:11 ET Menarini Group、2025年サンアントニオ乳がんシンポジウムにてエラセストラント（ORSERDU®）併用療法の第2相データをER+、HER2-転移性乳がん（mBC）患者を対象に発表
*PIK3CAmut8.3 [3.6 - 10.2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 23:19 ET Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025
*PIK3CAmut8,3 [3,6 - 10,2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
*PIK3CA突變8.3 [3.6 - 10.2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 11:38 ET El Grupo Menarini presenta datos de la combinación de fase 2 de Elacestrant (ORSERDU®) en cáncer de mama
* PIK3CAmut 8,3 [3,6 – 10,2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:49 ET 메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표
*PIK3CAmut8.3 [3.6 - 10.2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 15:17 ET Le groupe Menarini présente les données de la phase 2 sur l'association d'Elacestrant (ORSERDU®) chez des patientes atteintes d'un cancer du sein métastatique (mBC) ER+, HER2- lors du 2025 San Antonio Breast Cancer Symposium
*PIK3CAmut8.3 [3.6 - 10.2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
*PIK3CAmut8.3 [3.6 - 10.2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
*PIK3CAmut8.3 [3.6 - 10.2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
*PIK3CAmut8.3 [3.6 - 10.2]
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 08:30 ET Automotores Gildemeister SpA Announces Early Results and Extension of Early Exchange Time of Previously Announced Exchange Offers by AG Chile Holding II SpA for Outstanding 7.50% Junior Secured Notes due 2027 and 10.00% Subordinated Notes due 2035 and Related Consent Solicitations
to exchange (the "Existing Junior Notes Exchange Offer") any and all of their outstanding Existing Junior Notes for new 7.50% Senior Secured PIK Toggle Notes due 2032 (the "New 2032 Notes") to be issued by AG Chile Holding II SpA, a newly incorporated holding company (the "Issuer"),
More news about: Automotores Gildemeister SpA
Dec 04, 2025, 08:30 ET Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
Spotlight 10. December 12, 2025. 8:12-8:15 AM CSTPosters Include:Outcomes in patients with PIK3CA-mutated breast cancer treated with metformin. #PS1-11-11Poster Session 1. December 10, 2025. 12:30-2:00 PM CSTEvaluation
More news about: Caris Life Sciences
Dec 01, 2025, 17:31 ET Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
treatment strategies.Emerging Molecular Targets Driving Next-Gen TherapiesEmerging targets such as KRAS G12C, NTRK fusions, and PIK3CA mutations provide new opportunities for drug development.Growing CRC Clinical Trial ActivitiesSeveral colorectal cancer therapies
More news about: DelveInsight Business Research, LLP